Gamestop (GME) Offering Possible 8.11% Return Over the Next 17 Calendar Days

Gamestop's most recent trend suggests a bearish bias. One trading opportunity on Gamestop is a Bear Call Spread using a strike $190.00 short call and a strike $200.00 long call offers a potential 8.11% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bear Call Spread were to expire worthless, which would occur if the stock were below $190.00 by expiration. The full premium credit of $0.75 would be kept by the premium seller. The risk of $9.25 would be incurred if the stock rose above the $200.00 long call strike price.

The 5-day moving average is moving down which suggests that the short-term momentum for Gamestop is bearish and the probability of a decline in share price is higher if the stock starts trending.

The 20-day moving average is moving down which suggests that the medium-term momentum for Gamestop is bearish.

The RSI indicator is at 47.7 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here

LATEST NEWS for Gamestop

When Will AMC Entertainment and GameStop Be Profitable?
Mon, 29 Mar 2021 10:06:00 +0000
Investing in the stock market can be quite the adventure. In 2021, an unexpected catalyst has taken over as a key market driver: retail investors. Beginning in mid-January, retail investors from Reddit's WallStreetBets chat room began banding together to buy shares and out-of-the-money call options in companies with high levels of short interest (i.e., stocks where a lot of investors are betting on a share price decline).

Benzinga's Bulls And Bears Of The Week: Amazon, Citigroup, Facebook, GameStop, Intel And More
Sun, 28 Mar 2021 11:31:49 +0000
Benzinga has examined the prospects for many investor favorite stocks over the past week. The past week's bullish calls included e-commerce, social media and banking leaders. A struggling retailer and semiconductor giant were among the bearish calls that were seen. Federal Reserve commentary on share buybacks helped boost the market on Friday, and the Dow Jones industrials and the S&P 500 ended the week more than 1% higher. The tech-heavy Nasdaq lagged, though, down fractionally for the week. Last week was the anniversary of the pandemic-selling low. It was a week marked by quarter-end rebalancing, rising Treasury yields and a rotation to value and reopening stocks, as well as supply-chain headaches and increasing global virus worries. Meanwhile, Wall Street looks forward to a waning pandemic and a new earnings reporting season. Also last week, a pharmaceutical giant not only was testing its COVID-19 vaccine on children, but working on an oral version and also getting ready for the next vaccines. Signs of a recovering U.S. economy included expansion plans at airlines and for theme parks, as well as encouraging auto sales forecasts. And there were a couple of regulatory issues of note and a mishap in global shipping. Through it all, Benzinga continued to examine the prospects for many of the stocks most popular with investors. Here are a few of this past week's most bullish and bearish posts that are worth another look. Bulls Analysts are highly bullish on Amazon.com, Inc. (NASDAQ: AMZN) and four other stocks despite inflation fears. So says Rachit Vats' “5 Stocks Top Analysts Are Heavily Bullish On Heading Into April.” In Madhukumar Warrier's “Tech Stocks Aren't A Buy Right Now But One Giant Is An Exception, Says Analyst,” see why Facebook Inc. (NASDAQ: FB) stands out from its tech sector peers. In “BofA Raises Bank Stock Price Targets, Sees Potential For ‘Significant EPS Upside',” Wayne Duggan focuses on why Citigroup Inc (NYSE: C) is a top pick as momentum among big bank stocks is likely to continue. Jayson Derrick's “Why Tigress Financial Is Bullish On Verizon, AT&T” discusses why one key analyst has turned positive on Verizon Communications Inc. (NYSE: VZ) and remains bullish on AT&T Inc. (NYSE: T). “Inovio Has ‘Bigger Value Drivers' Outside Of COVID-19 Vaccine Program: BofA Analyst” by Shanthi Rexaline examines the other value drivers at Inovio Pharmaceuticals, Inc. (NASDAQ: INO). For additional bullish calls of the past week, have a look at the following: Small-Cap Stocks Have Been On The Rise In Recent Months, Here's What Traders Can Expect In 2021 5 REIT Stocks You May Want To Consider Cramer Sees These Stocks As Likely Beneficiaries Of ‘Easter Rally' Bears In Chris Katje's “GameStop Analysts React To Q4 Earnings: Company Needs ‘Some Magic Beans And Pixie Dust'” find out why the GameStop Corp (NYSE: GME) earnings report was anything but a fairy tale. Ark Innovation ETF (NYSE: ARKK) has lost a third of its value since last month's all-time high, according to “Options Traders May Be Fearing More Downside For Cathie Wood's ARKK” by Melanie Schaffer. How much further will it drop? In “4 Intel Analysts On ‘Unleashed' Event, The Risks Of Chipmaker's Foundry Plans,” Shanthi Rexaline looks at reasons to remain skeptical about the prospects for Intel Corporation (NASDAQ: INTC) stock. “Wells Fargo Downgrades AMC Networks, Discovery, ViacomCBS: What Investors Need To Know” by Phil Hall points out why ViacomCBS Inc. (NASDAQ: VIAC) and its peers already may have peaked. Priya Nigam's “Why Did BofA Downgrade Bausch Health?” shows why one analyst believes a proposed restructuring of Bausch Health Companies Inc (NYSE: BHC) may not create the desired value for investors. For additional bearish takes, be sure to check out these posts: Are Cracks Forming In The ‘4 Pillars' Supporting The Stock Market? Bitcoin Has Dropped To Below ,000 And Analyst Says Further Downside On The Horizon Why Cathie Wood's Ark Is Unimpressed With Volkswagen's EV Battery Plans At the time of this writing, the author had no position in the mentioned equities. Keep up with all the latest breaking news and trading ideas by following Benzinga on Twitter. Photo courtesy of Pixabay. See more from BenzingaClick here for options trades from BenzingaBarron's Latest Picks And Pans: Space Race Picks, Eli Lilly, GameStop, Splunk And MoreThe Past Week's Notable Insider Buys Include Coupang, Keurig Dr Pepper, IPOs And More© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Could AMC, GameStop, or Sundial Shares Fall to $0?
Sun, 28 Mar 2021 10:06:00 +0000
Last year, it was Wall Street navigating its way through an unprecedented pandemic. Beginning in mid-January, retail investors from Reddit's WallStreetBets chat room began allying with each other to take on institutional investors and hedge funds with large short positions in select stocks. In simple terms, these retail investors purchased shares and out-of-the-money call options on stocks with high levels of short interest to create a short squeeze — i.e., an event where pessimists rush for the exit, which causes a rising stock to really take off.

Citadel’s Griffin warns of inflation risk to markets enjoying retail trading boom
Sun, 28 Mar 2021 00:00:00 +0000
The retail stock trading frenzy will reach a new crescendo in the coming weeks thanks to the US government’s stimulus cheques but the inflation this support could ignite represents a threat to the stock market bull run, according to Citadel’s Ken Griffin. The founder of one of the world’s biggest hedge funds thinks the $1,400 sent out to millions of Americans this month is likely to fuel another spasm of retail trading before activity settles down to a still-elevated level.

5 High-Flying Stocks That Turned $200,000 Into More Than $1 Million in 3 Months
Sat, 27 Mar 2021 17:36:00 +0000
Since hitting this bottom, the tech-heavy Nasdaq Composite has more than doubled, while the broad-based S&P 500 has gained as much as 77%. Whereas the Nasdaq hasn't gone anywhere over the trailing three-month period (through March 24), five stocks have catapulted higher. To start with, a $200,000 investment clinical-stage biotech stock Cassava Sciences (NASDAQ: SAVA) would have returned a cool 523% over three months.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.